Abstract
help with a variety of treatments, including counseling, nicotine replacement therapy (patches, gum, lozenges, or inhalers), and medications. Some smokers use these treatments and succeed; for many, however, the discomfort of withdrawal and craving for nicotine lead to relapse. Recent NIDAfunded research suggests that our genes may partly explain this variable success. The research evaluated the effect of an enzyme, designated CYP2B6, on craving and relapse. This enzyme breaks down nicotine in the brain. Some people’s genes produce a more active form of the enzyme, while others have a less active form. Dr. Caryn Lerman at the NIDAand NCIsupported Transdisciplinary Tobacco Use Research Center (TTURC) at the University of Pennsylvania found that
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
